Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 28, 2020

View Archived Issues

Epigenetic resistance to PARP inhibitors

Microglial pruning under the influence links alcohol to anxiety

Hoth reports research findings on ability of HT-003 to block acne pathogenic gene expression

Australian researchers uncover critical aspects of MR1 protein to boost immune system

FDA clears IND application for ANK-700

Shouyao Holdings describes new FGFR-4 inhibitors

New baculoviral IAP repeat-containing protein 5 inhibitors patented by Trillium Therapeutics

Popular opinion correct on fear, anxiety

Pivotal phase III CheckMate-274 study of Opdivo meets primary endpoints

FDA clears new IND for ADXS-504

Voronoi synthesizes new dual specificity protein kinase TTK inhibitors

Sichuan Kelun-Biotech Biopharmaceutical discovers PRMT5 inhibitors

IL-20 blockade can be a promising treatment for PDAC, synergizing with anti-PD-1 therapy

New phosphatidylserine synthase inhibitors disclosed by Daiichi Sankyo

Enhertu approved in Japan for HER2-positive metastatic gastric cancer

Novavax initiates U.K. phase III study of NVX-CoV2373 COVID-19 vaccine candidate

Japan first to approve Ecclock for primary axillary hyperhidrosis

Clinical activity seen with SNS-301 and pembrolizumab in head and neck cancer trial

Serum Fetuin-B as potential biomarker of metabolic syndrome and insulin resistance

Phase II trial reveals activity of retifanlimab in chemotherapy-naive Merkel cell carcinoma

FDA approves Nucala for hypereosinophilic syndrome

Basilea initiates phase I/II study of derazantinib in advanced gastric cancer

Ayvakyt approved in E.U. for unresectable or metastatic PDGFRA D842V mutant GIST

Jyseleca receives E.U. approval for moderate to severe active rheumatoid arthritis

Lenvatinib effective in combo with pembrolizumab in PD-L1-refractory melanoma

FDA clears IND for phase II study of Stemedica's itMSCs for COVID-19

ImmVira studies T-3011 in phase I for advanced cutaneous or subcutaneous malignancies

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...